Recent progress in pathogenesis and management of colorectal cancer. Eighteenth International Symposium of the Hiroshima Cancer Seminar, November 2008

Wataru Yasui, Hisao Ito, Raymond N. Du Bois, Eiichi Tahara

Research output: Contribution to journalArticle

Abstract

This symposium presented recent progress of the pathogenesis and treatment of colorectal cancer (CRC). Field cancerization by modified stem cells may be the earliest changes associated with CRC. CD34+-immature myeloid cells are deeply involved in CRC invasion. Inflammatory mediators stimulate cancer progression. We must strive for a better understanding of the molecular mechanisms responsible for this connection. Serial analysis of gene expression data analysis has identified novel biomarkers for cancer detection and possible prognosis. Better endoscopic techniques are suitable for early detection and resection of colonic lesions. Chemoprevention of CRC using sulindac and aberrant crypt foci as a clinical endpoint have shown glutathione S-transferase π as a possible new target. A new drug delivery system using nanoparticles is being developed with SN-38, a biologically active metabolite of irinotecan. Survival of Japanese male patients with CRC is the best in the world due to lymph node dissection and surveillance. The use of laparoscopic surgery has increased, especially for advanced cancer. A treatment trial by the Sanin Study Group suggests that modified 5-fluorouracil and leucovorin with oxaliplatin treatment could be carried out in elderly patients. A great deal of information for understanding carcinogenesis and treatment has provided us with novel strategies for the management and prevention of CRC.

Original languageEnglish (US)
Pages (from-to)978-981
Number of pages4
JournalCancer Science
Volume100
Issue number5
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Colorectal Neoplasms
irinotecan
Neoplasms
oxaliplatin
Aberrant Crypt Foci
Sulindac
Leucovorin
Chemoprevention
Myeloid Cells
Therapeutics
Drug Delivery Systems
Tumor Biomarkers
Glutathione Transferase
Lymph Node Excision
Fluorouracil
Laparoscopy
Nanoparticles
Carcinogenesis
Stem Cells
Gene Expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Recent progress in pathogenesis and management of colorectal cancer. Eighteenth International Symposium of the Hiroshima Cancer Seminar, November 2008. / Yasui, Wataru; Ito, Hisao; Du Bois, Raymond N.; Tahara, Eiichi.

In: Cancer Science, Vol. 100, No. 5, 2009, p. 978-981.

Research output: Contribution to journalArticle

Yasui, Wataru ; Ito, Hisao ; Du Bois, Raymond N. ; Tahara, Eiichi. / Recent progress in pathogenesis and management of colorectal cancer. Eighteenth International Symposium of the Hiroshima Cancer Seminar, November 2008. In: Cancer Science. 2009 ; Vol. 100, No. 5. pp. 978-981.
@article{467091733d904ba79436b6c9664f0e75,
title = "Recent progress in pathogenesis and management of colorectal cancer. Eighteenth International Symposium of the Hiroshima Cancer Seminar, November 2008",
abstract = "This symposium presented recent progress of the pathogenesis and treatment of colorectal cancer (CRC). Field cancerization by modified stem cells may be the earliest changes associated with CRC. CD34+-immature myeloid cells are deeply involved in CRC invasion. Inflammatory mediators stimulate cancer progression. We must strive for a better understanding of the molecular mechanisms responsible for this connection. Serial analysis of gene expression data analysis has identified novel biomarkers for cancer detection and possible prognosis. Better endoscopic techniques are suitable for early detection and resection of colonic lesions. Chemoprevention of CRC using sulindac and aberrant crypt foci as a clinical endpoint have shown glutathione S-transferase π as a possible new target. A new drug delivery system using nanoparticles is being developed with SN-38, a biologically active metabolite of irinotecan. Survival of Japanese male patients with CRC is the best in the world due to lymph node dissection and surveillance. The use of laparoscopic surgery has increased, especially for advanced cancer. A treatment trial by the Sanin Study Group suggests that modified 5-fluorouracil and leucovorin with oxaliplatin treatment could be carried out in elderly patients. A great deal of information for understanding carcinogenesis and treatment has provided us with novel strategies for the management and prevention of CRC.",
author = "Wataru Yasui and Hisao Ito and {Du Bois}, {Raymond N.} and Eiichi Tahara",
year = "2009",
doi = "10.1111/j.1349-7006.2009.01109.x",
language = "English (US)",
volume = "100",
pages = "978--981",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Recent progress in pathogenesis and management of colorectal cancer. Eighteenth International Symposium of the Hiroshima Cancer Seminar, November 2008

AU - Yasui, Wataru

AU - Ito, Hisao

AU - Du Bois, Raymond N.

AU - Tahara, Eiichi

PY - 2009

Y1 - 2009

N2 - This symposium presented recent progress of the pathogenesis and treatment of colorectal cancer (CRC). Field cancerization by modified stem cells may be the earliest changes associated with CRC. CD34+-immature myeloid cells are deeply involved in CRC invasion. Inflammatory mediators stimulate cancer progression. We must strive for a better understanding of the molecular mechanisms responsible for this connection. Serial analysis of gene expression data analysis has identified novel biomarkers for cancer detection and possible prognosis. Better endoscopic techniques are suitable for early detection and resection of colonic lesions. Chemoprevention of CRC using sulindac and aberrant crypt foci as a clinical endpoint have shown glutathione S-transferase π as a possible new target. A new drug delivery system using nanoparticles is being developed with SN-38, a biologically active metabolite of irinotecan. Survival of Japanese male patients with CRC is the best in the world due to lymph node dissection and surveillance. The use of laparoscopic surgery has increased, especially for advanced cancer. A treatment trial by the Sanin Study Group suggests that modified 5-fluorouracil and leucovorin with oxaliplatin treatment could be carried out in elderly patients. A great deal of information for understanding carcinogenesis and treatment has provided us with novel strategies for the management and prevention of CRC.

AB - This symposium presented recent progress of the pathogenesis and treatment of colorectal cancer (CRC). Field cancerization by modified stem cells may be the earliest changes associated with CRC. CD34+-immature myeloid cells are deeply involved in CRC invasion. Inflammatory mediators stimulate cancer progression. We must strive for a better understanding of the molecular mechanisms responsible for this connection. Serial analysis of gene expression data analysis has identified novel biomarkers for cancer detection and possible prognosis. Better endoscopic techniques are suitable for early detection and resection of colonic lesions. Chemoprevention of CRC using sulindac and aberrant crypt foci as a clinical endpoint have shown glutathione S-transferase π as a possible new target. A new drug delivery system using nanoparticles is being developed with SN-38, a biologically active metabolite of irinotecan. Survival of Japanese male patients with CRC is the best in the world due to lymph node dissection and surveillance. The use of laparoscopic surgery has increased, especially for advanced cancer. A treatment trial by the Sanin Study Group suggests that modified 5-fluorouracil and leucovorin with oxaliplatin treatment could be carried out in elderly patients. A great deal of information for understanding carcinogenesis and treatment has provided us with novel strategies for the management and prevention of CRC.

UR - http://www.scopus.com/inward/record.url?scp=65349113687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349113687&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01109.x

DO - 10.1111/j.1349-7006.2009.01109.x

M3 - Article

C2 - 19220296

AN - SCOPUS:65349113687

VL - 100

SP - 978

EP - 981

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -